The pressure is growing on researchers and sponsors to share de-identified clinical data responsibly as global demand for clinical trial transparency continues to increase. Read this whitepaper to learn more about:
- The different Health Agencies’ policies
- Consequences of non-compliance
- Limitations of conventional de-identification strategies
- Solutions to obstacles and regulatory requirements